Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company pioneering oral therapies for endocrine disorders and related tumors. This news hub provides investors and industry professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Access official press releases, financial reports, and scientific updates related to CRNX's lead candidates: paltusotine for acromegaly/carcinoid syndrome and atumelnant targeting adrenal disorders. Our curated news collection enables efficient tracking of therapeutic innovations in rare diseases, partnership announcements, and market-moving events.
Content spans clinical data publications, FDA communications, executive leadership updates, and research collaborations. Bookmark this page for direct access to primary-source information about CRNX's novel small molecule therapies and their development pathways.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the early release of late-breaking abstracts for ENDO 2024, focusing on a Phase 2 study of atumelnant (CRN04894) for Congenital Adrenal Hyperplasia (CAH). Initial data from four subjects were submitted, with plans to present extended results from six subjects in cohort 1 and more in cohort 2 at ENDO 2024. Detailed findings will be shared on June 3, 2024, during the Late-Breaking Poster Presentation session.
Crinetics Pharmaceuticals announced on May 10, 2024, the granting of non-qualified stock options to fifteen new non-executive employees under the 2021 Employment Inducement Incentive Award Plan. The options have an exercise price of $48.00 per share and will vest over four years. This inducement is pursuant to Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals reported strong financial results for Q1 2024, highlighted by positive data from Phase 2 studies of Atumelnant (CRN04894) in congenital adrenal hyperplasia and ACTH-dependent Cushing’s Syndrome. The company is set to present late-breaking results at ENDO in June. Additionally, a Phase 3 study for paltusotine in carcinoid syndrome is expected to start by year-end. Crinetics also secured $350 million in financing to support commercial readiness and pipeline development, totaling $901.0 million in cash and equivalents as of March 31, 2024.
Crinetics Pharmaceuticals will present advancements from their Atumelnant (CRN04894) and Paltusotine development programs at ENDO 2024. Initial data from the Phase 2 trial of Atumelnant in Congenital Adrenal Hyperplasia and findings from the Phase 1b/2a ACTH-Dependent Cushing’s Syndrome trial will be showcased. Data from Phase 3 PATHFNDR 1 and 2 trials of Paltusotine in Acromegaly, along with new long-term safety and efficacy findings, will also be presented. Crinetics aims to build the premier endocrine-focused pharmaceutical company with these developments.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will report its first quarter 2024 financial results on May 9, 2024. The company will host a conference call to discuss financial results and provide a business update. Investors can participate via phone or webcast.
FAQ
What is the current stock price of Crinetics Pharmaceuticals (CRNX)?
What is the market cap of Crinetics Pharmaceuticals (CRNX)?
